Programmable Implantable Cardiac Defibrillator Offers Improved Safety

A next-generation implantable cardiac defibrillator (ICD) features a state-of-the-art battery technology that delivers 37 Joules of energy to the heart.

The Paradym 8750 cardiac resynchronization therapy defibrillator (CRT-D) is designed to allow more flexibility in the management of cardiac resynchronization and anti-tachyarrhythmia therapy in heart failure patients, by offering consistent charge times throughout the life of the device (10 seconds at beginning of life and 13 seconds at the elective replacement indicator (ERI) point), improved longevity, and a six-month ERI to end of service (EOS) period, twice as long as current ICDs.

A programmable brady-tachy overlap (BTO) feature unlocks pacing and detection to ensure the delivery of resynchronization therapy at high pacing rates during exercise, without compromising the management of slow ventricular tachycardia (VT). The Paradym CRT also features the proprietary PARAD+ detection algorithm, reducing the absolute risk of experiencing an inappropriate shock to only 5%, due to increased specificity. The Paradym CRT 8750 is a product of Sorin Group (Milano, Italy), and has been approved by the U.S. food and Drug Administration (FDA).

"I'm impressed with the Sorin technology; they have managed to pack a lot of power into a small can without compromising on features, good charge times or longevity,” said Dwight Reynolds, M.D., chief of the cardiovascular section at the University of Oklahoma Health Sciences Center (Oklahoma City, USA), who performed the first U.S. implant of Paradym CRT. "I especially like the six months longevity post-ERI and the PARAD+ discrimination algorithm to minimize inappropriate shocks…that is extremely important to both my patients and myself.”

Related Links:
Sorin Group